Document is current

Article History

Received: 20 August 2024

Accepted: 17 October 2024

First Online: 4 November 2024

Declarations

:

: Masayuki Yoshida declares consultation with Lilly Japan and Roche Japan, along with receiving speaker honoraria from Agilent Technologies, Chugai Pharma, Ono Yakuhin, MSD, and Daiichi Sankyo. Shinobu Masuda discloses their position on the advisory board in HER2 IHC at Roche Diagnostic K.K. Tomo Osako discloses honoraria for speaking at symposia from Diaceutics, Daiichi Sankyo, and Exact Sciences, as well as a position on the advisory board with Daiichi Sankyo and Roche Diagnostics. Amiko Hayashi is an employee of Roche Diagnostics K.K. in the non-commercial division of Medical and Scientific Affairs and owns stocks. Ana Richelia Jara-Lazaro is an employee of Roche Diagnostics Asia Pacific in the non-commercial division of Medical and Scientific Affairs and owns stocks. Rie Horii has received research grants from Roche Diagnostics K.K and has received a speaker honorarium from Roche Diagnostics K.K, Chugai Pharmaceutical Co Ltd, and Daiichi sankyo Co Ltd. All the other authors declare that they have no conflicts of interest.

: This study was approved by the Ethics Committee of the Saitama Cancer Center (No. 1462) and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki. The specimens used in this study were obtained from a previous study approved by the Saitama Cancer Center (No. 1062).

: Comprehensive consent was obtained from all study participants.

: Not applicable.